Kim M. Keppler-Noreuil, MD
Professor of Pediatrics
Division Chief of Genetics & Metabolism
University of Wisconsin School of Medicine and Public Health

Before recently joining University of Wisconsin School of Medicine and Public Health as Division Chief of Genetics & Metabolism, Professor of Pediatrics, and during my 24-year career in Medical Genetics, I held positions of Professor of Pediatrics in the Division of Medical Genetics at the University of Iowa Carver College of Medicine, Clinical Director of the Iowa Registry of Congenital & Inherited Disorders, Clinical Associate Investigator/Senior Research Physician at the NHGRI /Metabolic Genetics and Medical Genomics Branch. These positions provided me with a breadth of clinical and research experience in epidemiology of birth defects, clinical genomics and dysmorphology. I contributed to the development of case classification guidelines for the National Birth Defect Prevention Study (NBDPS), a multicenter study of genetic and environmental risk factor of over 30 major birth defects, as well as being the reviewer /classifier for NBDPS cases. I have continued to provide expertise on local (IA) and NBDPS (pooled data) research studies. My areas of research and publications have included clinical delineation of multiple malformation syndromes, and studies of epidemiology and pathogenetic mechanisms of birth defects, inherited and chromosomal disorders. Part of my current research interests involving the Centers for Birth Defects Research and Prevention (CBDRP) data have been in descriptive and genetics studies of OEIS complex/ cloacal exstrophy, Dandy-Walker malformation and hydrocephalus. In my position at the NHGRI/NIH my additional research interests include natural history, clinical characterization, genetic studies, and therapeutic interventions of somatic overgrowth disorders, including Proteus syndrome and PIK3CA-Related Overgrowth Spectrum (PROS), as well as other malformations and rare genetic disorders, including OEIS complex/cloacal exstrophy, and Bardet-Biedl syndrome. As principal investigator and co-lead of the PIK3CA-Related Overgrowth Multinational Investigation of Sirolimus Efficacy (PROMISE), we initiated the pilot treatment trial in collaboration the University of Cambridge, UK and University of Dijon, France as part of the Consortium for Overgrowth Disorder Management and Evaluation of Therapeutics (COMET). I also led a therapeutic clinical trial for Proteus syndrome. Both these efforts in genetic characterization and therapeutics have led to clinical trials and longitudinal study of segmental overgrowth and vascular disorders.